This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Atypical haemolytic uraemic syndrome (HUS)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated disease associated with poor outcomes if untreated

  • the endothelial damage caused by thrombotic microangiopathy (TMA) can result in life-threatening manifestations of the disease, including kidney failure and extrarenal tissue damage
  • prior to the availability of targeted treatment with complement C5 inhibitors, the prognosis of aHUS both in pediatric and adult patients was poor- around 29% of children required dialysis or died within 1 year and 48% reached chronic kidney disease (CKD) stage 5 or death at 3 years despite plasma therapy
  • subdivision of this disease is possible, including recognition of those with anti-factor H autoantibodies (a subgroup which accounts for about 10% of paediatric aHUS)
    • definition of aHUS has been broadened to include other rare forms of HUS including diacylglycerol kinase E and Cobalamin C deficiency, as well as HUS with no clear precipitant
  • diagnosis
    • based on the presence of thrombocytopenia, microangiopathic haemolysis, and kidney injury and the exclusion of other forms of HUS or thrombotic thrombocytopenic purpura (TTP)

NICE state (2):

  • Ravulizumab is recommended, within its marketing authorisation, as an option for treating atypical haemolytic uraemic syndrome (aHUS) in people weighing 10 kg or more:
    • who have not had a complement inhibitor before or
    • whose disease has responded to at least 3 months of eculizumab treatment


  • ravulizumab
    • is a humanized monoclonal antibody (mAb) engineered from eculizumab to target the same complement C5 epitope while decreasing drug clearance and reducing the required frequency of infusions
    • incorporates selective amino acid modifications to both increase the dissociation rate of the mAb:C5 complex in the acidic early endosome at pH 6.0 and enhance the efficiency of neonatal Fc receptor-mediated antibody recycling, leading to an extended duration of terminal complement inhibition
    • has a mean terminal elimination half-life that is over 4 times greater than that of eculizumab (about 51.8 days vs. about 11 days) and offers a reduced dosing frequency of 4-8 weeks vs. every 2-3 weeks, depending on bodyweight
  • eculizumab
    • has proved highly effective in children with aHUS
    • however, treatment regimen involves frequent intravenous infusions (every 2 weeks in patients weighing >10 kg), which can be particularly burdensome for pediatric patients and caregivers (1)


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page